Rice Hall James & Associates LLC Purchases Shares of 51,038 Haemonetics Corporation $HAE

Rice Hall James & Associates LLC acquired a new stake in shares of Haemonetics Corporation (NYSE:HAE) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 51,038 shares of the medical instruments supplier’s stock, valued at approximately $3,828,000.

Other hedge funds also recently made changes to their positions in the company. AQR Capital Management LLC lifted its stake in Haemonetics by 48.6% during the fourth quarter. AQR Capital Management LLC now owns 3,163,104 shares of the medical instruments supplier’s stock valued at $253,523,000 after purchasing an additional 1,034,226 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of Haemonetics by 994.7% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,380,102 shares of the medical instruments supplier’s stock valued at $110,615,000 after buying an additional 1,254,035 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Haemonetics by 21.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,326,057 shares of the medical instruments supplier’s stock valued at $74,731,000 after acquiring an additional 233,119 shares during the last quarter. North Peak Capital Management LLC lifted its position in shares of Haemonetics by 204.4% during the 4th quarter. North Peak Capital Management LLC now owns 1,102,992 shares of the medical instruments supplier’s stock valued at $88,405,000 after acquiring an additional 740,626 shares during the last quarter. Finally, Fort Washington Investment Advisors Inc. OH boosted its stake in shares of Haemonetics by 17.3% during the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 841,017 shares of the medical instruments supplier’s stock worth $47,400,000 after acquiring an additional 124,020 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Stock Down 0.9%

NYSE:HAE opened at $89.98 on Tuesday. The firm has a market capitalization of $4.09 billion, a price-to-earnings ratio of 44.11, a PEG ratio of 1.82 and a beta of 0.52. Haemonetics Corporation has a 1-year low of $47.31 and a 1-year high of $92.25. The company has a current ratio of 3.08, a quick ratio of 1.91 and a debt-to-equity ratio of 1.40. The business’s fifty day moving average price is $79.39 and its 200 day moving average price is $67.33.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.06. Haemonetics had a return on equity of 27.55% and a net margin of 7.12%.The firm had revenue of $339.38 million during the quarter, compared to the consensus estimate of $327.86 million. During the same period in the prior year, the business earned $1.10 EPS. The business’s revenue for the quarter was up 5.5% on a year-over-year basis. On average, sell-side analysts forecast that Haemonetics Corporation will post 5.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

HAE has been the topic of a number of recent research reports. Bank of America upgraded Haemonetics from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $72.00 to $80.00 in a report on Friday, May 22nd. JPMorgan Chase & Co. upped their target price on Haemonetics from $62.00 to $86.00 and gave the company a “neutral” rating in a report on Friday, August 7th. BTIG Research increased their price target on Haemonetics from $84.00 to $96.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Raymond James Financial reissued an “outperform” rating and issued a $105.00 price target on shares of Haemonetics in a research note on Friday, August 7th. Finally, Mizuho boosted their price objective on Haemonetics from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $90.89.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.